small molecule

BAXFENDY

BAXDROSTAT

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry

CompanyASTRAZENECA AB

Drug detail

Brand name	BAXFENDY
Active ingredient	BAXDROSTAT
Strength	2MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
9353081	February 2033	substance, product

Regulatory exclusivity

Code	Expires
NCE	May 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ASTRAZENECA AB